Detail akcie Allurion Tech Rg online

Business Summary: Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Balloon is swallowed as a capsule under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia. The Allurion Balloon is a procedure-less intragastric balloon that does not require any surgery, endoscopy, or anesthesia for placement. The balloon is swallowed in a capsule during a discrete outpatient office visit that takes approximately 15 minutes (though times may vary across different outpatient offices). The Allurion Virtual Care Suite is a cutting-edge digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Allurion Technologies Inc revenues decreased 56% to $11.6M. Net loss totaled $13.8M vs. income of $6M. Revenues reflect All other countries segment decrease of 59% to $7M, France segment decrease of 92% to $274K, United Kingdom segment decrease of 94% to $81K. Basic Earnings per Share excluding Extraordinary Items decreased from $1.99 to -$1.27.